Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients.
Some neurosteroids have been shown to display beneficial effects on neuroprotection in rodents. To investigate the physiopathological significance of neurosteroids in Alzheimer's disease (AD), we compared the concentrations of pregnenolone, pregnenolone sulfate (PREGS), dehydroepiandrosterone, dehydroepiandrosterone sulfate (DHEAS), progesterone, and allopregnanolone, measured by gas chromatography-mass spectrometry, in individual brain regions of AD patients and aged nondemented controls, including hippocampus, amygdala, frontal cortex, striatum, hypothalamus, and cerebellum. A general trend toward decreased levels of all steroids was observed in all AD patients' brain regions compared with controls: PREGS and DHEAS were significantly lower in the striatum and cerebellum, and DHEAS was also significantly reduced in the hypothalamus. A significant negative correlation was found between the levels of cortical beta-amyloid peptides and those of PREGS in the striatum and cerebellum and between the levels of phosphorylated tau proteins and DHEAS in the hypothalamus. This study provides reference values for steroid concentrations determined by gas chromatography-mass spectrometry in various regions of the aged human brain. High levels of key proteins implicated in the formation of plaques and neurofibrillary tangles were correlated with decreased brain levels of PREGS and DHEAS, suggesting a possible neuroprotective role of these neurosteroids in AD.
Weill-Engerer
Sébastien
S
INSERM U-488, Stéroïdes et Système Nerveux, 80 rue du Général Leclerc, 54276 Le Kremlin-Bicêtre, France. sebastien@kb.inserm.fr
David
Jean-Philippe
JP
Sazdovitch
Véronique
V
Liere
Philippe
P
Eychenne
Bernard
B
Pianos
Antoine
A
Schumacher
Michael
M
Delacourte
André
A
Baulieu
Etienne-Emile
EE
Akwa
Yvette
Y
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D000544:Alzheimer Disease / Q000378:metabolism*; D000679:Amygdala / Q000737:chemistry; D016229:Amyloid beta-Peptides / Q000032:analysis; D001923:Brain Chemistry; D002531:Cerebellum / Q000737:chemistry; D003342:Corpus Striatum / Q000737:chemistry; D019314:Dehydroepiandrosterone Sulfate / Q000032:analysis; D005260:Female; D005625:Frontal Lobe / Q000737:chemistry; D008401:Gas Chromatography-Mass Spectrometry; D006624:Hippocampus / Q000737:chemistry; D006801:Humans; D007031:Hypothalamus / Q000737:chemistry; D008297:Male; D011280:Pregnanolone / Q000032:analysis; D011284:Pregnenolone / Q000032:analysis; D011374:Progesterone / Q000032:analysis; D017433:Protein Structure, Secondary; D013256:Steroids / Q000032:analysis*; D016875:tau Proteins / Q000032:analysis / Q000737:chemistry
D016229:Amyloid beta-Peptides; D013256:Steroids; D016875:tau Proteins; C018370:pregnenolone sulfate; D011374:Progesterone; D019314:Dehydroepiandrosterone Sulfate; D011284:Pregnenolone; D011280:Pregnanolone